HCM
RCKT icon

Highline Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Highline Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-77,400
Closed -$4.25M – 24
2020
Q4 		$4.25M Buy
+77,400
New +$2.82M 2.08% 15
2019
Q1 		– Sell
-409,485
Closed -$6.07M – 42
2018
Q4 		$6.07M Buy
+409,485
New +$6.8M 0.41% 32

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Highline Capital Management's RCKT Position: Q1 2021 in Review

Highline Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2021, closing a stake of 77,400 shares — an estimated $4.25M sold.

Highline Capital Management first reported a position in RCKT in Q4 2018 and held it in 2 quarters. The position peaked at $6.07M in Q4 2018. 173 funds tracked by Wall St. Rank hold RCKT as of Q1 2021.

  • Highline Capital Management reported no remaining Rocket Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Highline Capital Management sold 77,400 Rocket Pharmaceuticals shares in Q1 2021, an estimated $4.25M.
  • Highline Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Highline Capital Management's Rocket Pharmaceuticals position peaked at $6.07M in Q4 2018.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2021.

Based on Highline Capital Management's 13F filing for Q1 2021, filed 17 May 2021.